The UMass M2D2 $100K Challenge announced award recipients at Mintz Levin, Boston on April 6th. Cre8MDI was honored to be recognized along with other emerging-technology companies, such as Innoblative Designs, Astraeus Technologies, Fluid-Screen, LaunchPad Medical, and Biorasis. In all, 72 companies competed for the recognition that goes along with the opportunity to present their technologies to potential investors and others in the medical device community.
Cre8MDI was awarded Honorable Mention and a cash prize for our presentation. We thank all the sponsors who made these grants possible and for their continued commitment to advancing health technologies. We also thank the M2D2 program staff for their efforts to execute a successful program with all the logistics behind such an event. Cre8MDI looks forward to the potential for future collaboration with M2D2, the UMass Lowell engineering departments, and UMass Worcester medical staff and researchers.
M2D2 Award Winners – Roy Wallen of Cre8MDI on far left.
UMASS M2D2 Press Release: http://blogs.uml.edu/m2d2/2016/04/17/mintz-levin-hosts-m2d2-100k-challenge-awards-event/
Every day at Cre8MDI words like “heart, cardio, arteries, blood pressure” and more are discussed, but this is not the norm across America. Many people never consider their heart, until it’s giving them trouble. As the most important muscle in your body, your heart’s condition should be a priority in your life.
The American Red Cross has campaigned to make February “Heart Month” with WEAR RED campaigns, jump rope competitions in elementary schools, and fundraising campaigns to bring to mind the heart and its well-being. Many organizations and clinics have joined the campaign to bring heightened awareness to the general population.
The American Heart Association has defined what it means to have ideal cardiovascular health. Known as “Life’s Simple 7,” these steps can help add years to your life:
Maintain a healthy weight
Engage in regular physical activity
Eat a healthy diet
Manage blood pressure
Take charge of cholesterol
Keep blood sugar, or glucose, at healthy level
The MedTech Strategist featured Cre8MDI as one of their “Start-ups to Watch” in their recent publication.
ABSTRACT: “The science behind the measurement of pulse wave velocity as a surrogate for arterial stiffness and vascular health is reaching a critical mass of acceptance. Cre8MDI aims to enter a prepared market with a simple, easy-to use diagnostic device that will reveal which patients are at risk of suffering future cardiac events.”
For access to the entire article: https://www.innovationinmedtech.com/product/article-purchase-start-ups-watch-cre8mdi-new-measurement-arterial-stiffness-aids-cardiac-risk-stratification-mary-stuart/
Friday, October 30th Cre8MDI, LLC was invited to present at the MassMEDIC MEDTECH Showcase in Waltham, MA. Roy Wallen spoke on behalf of the Cre8MDI team and shared about the development of the Cardio 1:1™ system and how it could change the face of cardiovascular disease prediction.
Twenty-two other technology companies presented from Massachusetts, California, and Canada. Each shared about their emerging technologies and plans to implement them into mainstream patient care. Introductions to many consultants and potential investors were made and we look forward to following up with these individuals and companies in the months to come.
Thank you to Tom Sommer, President of MassMEDIC, and Michael Phalen, chairman of MassMedic and Executive Vice President of Boston Scientific Corporation, as well as all the sponsors who made the MassMEDIC MEDTECH Showcase possible.
Cre8MDI is pleased to announce that it has been honored to receive a Milestone Achievement Grant (MAP) from the Massachusetts Life Science Center (MLSC) in the amount of $200,000. The MLSC Board approved the first round of Milestone Achievement Program on Tuesday, May 26th.
“The MLSC’s Milestone Achievement Program provides an excellent opportunity for early-stage companies to grow and develop within Massachusetts’ fast-growing innovation economy,” said Governor Charlie Baker.
This new grant program was created to address the need of early-stage life science companies to reach critical value. The MLSC awarded more than $2million in funds to Massachusetts companies in order to support their work toward completion or fulfillment of a defined milestone.
It was a very competitive grant program with many life science companies vying for the funds. The MSLC determined that Cre8MDI met all the criteria and had a clear milestone driven proposal. The Board of Directors, Peer Reviewers, SAB, and Center staff were involved with reviewing the company’s business plan, science and future potential.
“We are pleased to be supporting Cre8MDI with this grant funding to help the company achieve a milestone in their product development” said MLSC Vice President for Communications & Marketing Angus McQuilken. “Cre8MDI is part of a vibrant and growing life sciences community in the Merrimack Valley that is creating jobs, while bringing technologies to market that will improve patient care and human health.”
David Cassidy, President of Cre8MDI stated, “This grant will fund our next stage of development. We are pleased with the validation this grant provides our company as we move forward to predict cardiovascular disease with ease.”
Official MLSC Press Release: http://www.masslifesciences.com/news/announcements/
MAP Grant Press Release by Cre8MDI FINAL